NASDAQ: TRAWTraws Pharma Inc Stock
$0.63-0.01 (-1.56%)
Updated Apr 25, 2024
TRAW Price
$0.63
Fair Value Price
$0.95
Market Cap
$13.32M
52 Week Low
$0.55
52 Week High
$1.45
P/E
-0.7x
P/B
1.25x
P/S
69.25x
PEG
N/A
Dividend Yield
N/A
Revenue
$226.00k
Earnings
-$18.95M
Gross Margin
100%
Operating Margin
-8,384.07%
Profit Margin
-8,384.1%
Debt to Equity
1.13
Operating Cash Flow
-$18M
Beta
0.65
Next Earnings
May 13, 2024
Ex-Dividend
N/A
Next Dividend
N/A
TRAW Overview
Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer. It has two clinical-stage programs, including narazaciclib (ON 123300), a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent or in combination with other anti-cancer therapies; and oral rigosertib alone or in combination with PD-1 inhibitor, which is in Phase I/IIa for the treatment of progressive K-Ras mutated non-small cell lung cancer. The company develops a Phase Ib/II ISS with rigosertib monotherapy in patients with advanced squamous cell carcinoma associated with recessive dystrophic epidermolysis bullosa; and has a preclinical program comprising IV/oral rigosertib for COVID-19. It has a license agreement with SymBio Pharmaceuticals Limited; license, development, and commercialization agreement with Pint International SA.; and a license and collaboration agreement with HanX Biopharmaceuticals, Inc. for the development, registration, and commercialization of narazaciclib. Onconova Therapeutics, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how TRAW scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
TRAW ($0.63) is undervalued by 33.41% relative to our estimate of its Fair Value price of $0.95 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
TRAW ($0.63) is significantly undervalued by 33.41% relative to our estimate of its Fair Value price of $0.95 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
TRAW is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more TRAW due diligence checks available for Premium users.
Be the first to know about important TRAW news, forecast changes, insider trades & much more!
TRAW News
Valuation
TRAW fair value
Fair Value of TRAW stock based on Discounted Cash Flow (DCF)
Price
$0.63
Fair Value
$0.95
Undervalued by
33.73%
TRAW ($0.63) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
TRAW ($0.63) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
TRAW is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
TRAW price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.7x
Industry
15.41x
Market
40.97x
TRAW price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.25x
Industry
5.8x
TRAW is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
TRAW's financial health
Profit margin
Revenue
$56.0k
Net Income
-$4.2M
Profit Margin
-7,471.4%
TRAW's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
TRAW's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$22.7M
Liabilities
$12.0M
Debt to equity
1.13
TRAW's short-term assets ($22.66M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
TRAW's short-term assets ($22.66M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
TRAW's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
TRAW's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$4.4M
Investing
$0.0
Financing
$0.0
TRAW's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
TRAW vs Biotech Stocks
Traws Pharma Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.